WNT974

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

Wnt signalling pathway inhibitor, PORCN inhibitor

Related drugs:

NOTCH1 mutation	Squamous Cell Carcinoma of Head and Neck	NOTCH1 mutation	Squamous Cell Carcinoma of Head and Neck	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D
NOTCH1 C478F	Squamous Cell Carcinoma of Head and Neck	NOTCH1 C478F	Squamous Cell Carcinoma of Head and Neck	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D	WNT974 Sensitive: D – Preclinical WNT974 Sensitive : D

Associations
(2)